---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-037574"
form_type: "8-K"
ticker: "INDP"
cik: "0001857044"
company_name: "Indaptus Therapeutics, Inc."
filed_at: "2026-08-13T11:30:16+00:00"
generated_at: "2026-08-13T11:35:31.078222+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Indaptus discontinues Decoy20 enrollment, no active clinical programs; Q2 net loss $1.8M

## Summary
- Q2 2026 net loss $1.8M vs $5.2M in Q2 2025; six-month loss $4.3M vs $9.8M; EPS loss $0.02 vs $9.09.
- Decoy20 enrollment discontinued; no participants remain in any clinical study; no active clinical development programs.
- June 17, 2026 private placement: 20M shares at $0.60/share, $12.0M gross proceeds; cash+investments $11.6M at June 30.
- R&D expenses down 83% to $0.4M (Q2) and $0.9M (six months); G&A down 37% to $1.4M (Q2).
- Annual meeting elected David Natan, Tim Ruan, Dr. Johnny Fox Arrowsmith as Class II directors; approved 2026 equity plan.

## SEC filing metadata
- accession: 0001493152-26-037574
- form_type: 8-K
- ticker: INDP
- cik: 0001857044
- company_name: Indaptus Therapeutics, Inc.
- filed_at: 2026-08-13T11:30:16+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1857044/000149315226037574/0001493152-26-037574-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1857044/000149315226037574/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-037574
- JSON: https://secwatch.observer/filing/0001493152-26-037574.json
- Plain text: https://secwatch.observer/filing/0001493152-26-037574.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.